# Methyl 1-Boc-azetidine-3-carboxylate

| | |
|---|---|
| **Cat. No.:** | HY-40151 |
| **CAS No.:** | 610791-05-4 |
| **Molecular Formula:** | $C_{10}H_{17}NO_4$ |
| **Molecular Weight:** | 215.25 |
| **Target:** | ADC Linker; PROTAC Linkers |
| **Pathway:** | Antibody-drug Conjugate/ADC Related; PROTAC |
| **Storage:** | Pure form -20°C 3 years<br>4°C 2 years<br>In solvent -80°C 6 months<br>-20°C 1 month |



## BIOLOGICAL ACTIVITY

| | |
|---|---|
| **Description** | Methyl 1-Boc-azetidine-3-carboxylate is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Methyl 1-Boc-azetidine-3-carboxylate is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1] |
| **$IC_{50}$ & Target** | Non-cleavable Linker |
| **In Vitro** | ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1].<br>PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

## REFERENCES

[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337.

[2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA